Multiple diabetes indicators, one blood sample
SomaSignal® tests turn proteomic data into clinical metrics for diabetes
18 clinical metrics from 55 µL
of blood, including:
- Glucose tolerance
- Resting energy
- Visceral fat
- Cardiorespiratory fitness
- Alcohol impact
- Heart failure
Ideal for clinical trial
- Assess comorbidities, including fatty liver and heart disease
- Measure VO2 max without an exercise test
- Determine drug efficacy
- Identify at-risk patients
- Identify patients likely to respond
Measure drug effects
Anticipate adverse events
White paperDetection of low-abundance serum proteins associated with Prediabetes for predictive and prognostic purposesDiabetes mellitus refers to a family of metabolic disorders that are characterized by elevated blood glucose concentrations, or hyperglycemia. The International Diabetes Federation estimated that in 2015 there were 415 million diabetes cases worldwide in the 20-79 year old age group and predicted that number to increase to 640 million by 2040. In the whitepaper you will uncover: Predicting disease onset via clinical biomarkers Applying the SomaScan® Assay to accurately identify serum proteins associated with diabetic risk and outcome Other potential applications for the SomaScan Assay in diabetes research
WebinarProteomics reveals the hidden impact of interventions in diabetesType 2 diabetes typically manifests itself in adulthood, following years of progressively worsening health status, affecting multiple biological systems, pathways and organs. But beyond measuring HbA1c, it has been difficult and expensive to measure the impact of disease and/or interventions that might impact organ damage or risk. Large-scale proteomics is an emerging field that has recently been shown to not only capture real-time health status, but also to predict or prognose risks of future organ damage, morbidity and mortality. Proteomic models, developed from multiple large clinical and observational studies, have been utilized here to provide a holistic summary of metabolic health and risk of future adverse outcomes from individuals undergoing diabetes intervention. In this webcast, the impact of both therapeutic (drug) and lifestyle (diet and exercise) interventions will be discussed on a host of cardiometabolic and body composition measures in subjects undergoing intervention compared to placebo or standard of care. The speakers will discuss how these proteomic models can be implemented to design more precise treatment strategies for diabetic patients, moving the field ever closer to realizing the goal of providing personalized care.
Additional SomaSignal tests
The CVD, heart failure, and cardiorespiratory fiitness tests make up a subset of 22 SomaSignal tests available for research use. Any or all of the SomaSignal tests are available for a single flat cost.
The statements herein have not been evaluated by the Food and Drug Administration.